#recombinant proteins and peptides

[cailynnjohnson]

With years of experience, Creative Biolabs can offer an extensive range of recombinant proteins and peptides including orthopoxviruses family, parapoxviruses family, molluscipoxviruses family, yatapoxviruses family, capripoxviruses family, suipoxviruses family, leporipoxviruses family, and avipoxviruses family.

[girlactionfigure]

Immense pride, tinged with sadness. 

For those who would like to read the full list:

1908 MECHNIKOV, ELIE 

FOR THEIR WORK ON IMMUNITY

1908 EHRLICH, PAUL

FOR THEIR WORK ON IMMUNITY

1914 BARANY, ROBERT

FOR HIS WORK ON THE PHYSIOLOGY AND PATHOLOGY OF THE VESTIBULAR APPARATUS

1922 MEYERHOF, OTTO FRITZ 

FOR HIS DISCOVERY OF THE FIXED RELATIONSHIP BETWEEN THE CONSUMPTION OF 

OXYGEN AND THE METABOLISM OF LACTIC ACID IN THE MUSCLE

1930 LANDSTEINER, KARL 

FOR HIS DISCOVERY OF HUMAN BLOOD GROUPS

1936 LOEWI, OTTO 

FOR THEIR DISCOVERIES RELATING TO CHEMICAL TRANSMISSION OF NERVE IMPULSES

1944 ERLANGER, JOSEPH 

FOR THEIR DISCOVERIES RELATING TO THE HIGHLY DIFFERENTIATED FUNCTIONS OF SINGLE NERVE FIBRES

1945 CHAIN, ERNST BORIS 

FOR THE DISCOVERY OF PENICILLIN AND ITS CURATIVE EFFECT IN VARIOUS INFECTIOUS DISEASES

1946 MULLER, HERMANN J. 

FOR THE DISCOVERY OF THE PRODUCTION OF MUTATIONS BY MEANS OF X-RAY IRRADIATION

1947 CORI, GERTY THERESA, RADNITZ 

FOR THEIR DISCOVERY OF THE COURSE OF THE CATALYTIC CONVERSION OF GLYCOGEN

1950 REICHSTEIN, TADEUS 

FOR THEIR DISCOVERIES RELATING TO THE HORMONES OF THE ADRENAL CORTEX, THEIR STRUCTURE AND BIOLOGICAL EFFECTS

1952 WAKSMAN, SELMAN A. 

FOR HIS DISCOVERY OF STREPTOMYCIN, THE FIRST ANTIBIOTIC EFFECTIVE AGAINST TUBERCULOSIS

1953 LIPMANN, FRITZ ALBERT 

FOR HIS DISCOVERY OF CO-ENZYME A AND ITS IMPORTANCE FOR INTERMEDIARY METABOLISM

1953 KREBS, HANS ADOLF 

FOR HIS DISCOVERY OF THE CITRIC ACID CYCLE

1958 LEDERBERG, JOSHUA 

FOR HIS DISCOVERIES CONCERNING GENETIC RECOMBINATION AND THE ORGANISATION OF THE GENETIC MATERIAL OF BACTERIA

1959 KORNBERG, ARTHUR 

FOR THEIR DISCOVERY OF THE MECHANISMS IN THE BIOLOGICAL SYNTHESIS OF RIBONUCLEIC ACID AND DEOXYRIBONUCLEIC ACID

1964 BLOCH, KONRAD 

FOR THEIR DISCOVERIES CONCERNING THE MECHANISM AND REGULATION OF THE CHOLESTEROL AND FATTY ACID METABOLISM

1965 JACOB, FRANCOIS 

FOR THEIR DISCOVERIES CONCERNING GENETIC CONTROL OF ENZYME AND VIRUS SYNTHESIS

1965 LWOFF, ANDRE

FOR THEIR DISCOVERIES CONCERNING GENETIC CONTROL OF ENZYME AND VIRUS SYNTHESIS

1967 WALD, GEORGE 

FOR THEIR DISCOVERIES CONCERNING THE PRIMARY PHYSIOLOGICAL AND CHEMICAL VISUAL PROCESSES IN THE EYE

1968 NIRENBERG, MARSHALL W. 

FOR THEIR INTERPRETATION OF THE GENETIC CODE AND ITS FUNCTION IN PROTEIN SYNTHESIS

1969 LURIA, SALVADOR E. 

FOR THEIR DISCOVERIES CONCERNING THE REPLICATION MECHANISM AND THE GENETIC STRUCTURE OF VIRUSES

1970 KATZ, BERNARD

FOR THEIR DISCOVERIES CONCERNING THE HUMORAL TRANSMITTERS IN THE NERVE TERMINALS AND THE MECHANISM

FOR THEIR STORAGE, RELEASE AND INACTIVATION

1970 AXELROD, JULIUS 

FOR THEIR DISCOVERIES CONCERNING THE HUMORAL TRANSMITTERS IN THE NERVE TERMINALS AND THE MECHANISM

FOR THEIR STORAGE, RELEASE AND INACTIVATION

1972 EDELMAN, GERALD M. 

FOR THEIR DISCOVERIES CONCERNING THE CHEMICAL STRUCTURE OF ANTIBODIES

1975 TEMIN, HOWARD M.

FOR THEIR DISCOVERIES CONCERNING THE INTERACTION BETWEEN TUMOR VIRUSES AND THE GENETIC MATERIAL OF THE CELL

1975 BALTIMORE, DAVID 

FOR THEIR DISCOVERIES CONCERNING THE INTERACTION BETWEEN TUMOR VIRUSES AND THE GENETIC MATERIAL OF THE CELL

1976 BLUMBERG, BARUCH S. 

FOR THEIR DISCOVERIES CONCERNING NEW MECHANISMS FOR THE ORIGIN AND DISSEMINATION OF INFECTIOUS DISEASES

1977 YALOW, ROSALYN 

FOR THE DEVELOPMENT OF RADIOIMMUNOASSAYS OF PEPTIDE HORMONES

1977 SCHALLY, ANDREW V. 

FOR THEIR DISCOVERIES CONCERNING THE PEPTIDE HORMONE PRODUCTION OF THE BRAIN

1978 NATHANS, DANIEL 

FOR THE DISCOVERY OF RESTRICTION ENZYMES AND THEIR APPLICATION TO PROBLEMS OF MOLECULAR GENETICS

1980 BENACERRAF, BARUJ 

FOR THEIR DISCOVERIES CONCERNING GENETICALLY DETERMINED STRUCTURES ON THE CELL SURFACE THAT

REGULATE IMMUNOLOGICAL REACTIONS

1984 MILSTEIN, CESAR 

FOR THEORIES CONCERNING THE SPECIFICITY IN DEVELOPMENT AND CONTROL OF THE IMMUNE SYSTEM AND THE DISCOVERY OF THE

PRINCIPLE FOR PRODUCTION OF MONOCLONAL ANTIBODIES

1985 BROWN, MICHAEL S. 

FOR THEIR DISCOVERIES CONCERNING THE REGULATION OF CHOLESTEROL METABOLISM

1985 GOLDSTEIN, JOSEPH L. 

FOR THEIR DISCOVERIES CONCERNING THE REGULATION OF CHOLESTEROL METABOLISM

1986 COHEN, STANLEY 

FOR THEIR DISCOVERIES OF GROWTH FACTORS

1986 LEVI-MONTALCINI, RITA 

FOR THEIR DISCOVERIES OF GROWTH FACTORS

1988 ELION, GERTRUDE B. 

FOR THEIR DISCOVERIES OF IMPORTANT PRINCIPLES FOR DRUG TREATMENT

1989 VARMUS, HAROLD E. 

FOR THEIR DISCOVERY OF THE CELLULAR ORIGIN OF RETROVIRAL ONCOGENES

1994 RODBELL, MARTIN 

FOR THEIR DISCOVERY OF G-PROTEINS AND THE ROLE OF THESE PROTEINS IN SIGNAL TRANSDUCTION IN CELLS

1994 GILMAN, ALFRED G. 

FOR THEIR DISCOVERY OF G-PROTEINS AND THE ROLE OF THESE PROTEINS IN SIGNAL TRANSDUCTION IN CELLS

1997 PRUSINER, STANLEY B. 

FOR HIS DISCOVERY OF PRIONS - A NEW BIOLOGICAL PRINCIPLE OF INFECTION

1998 FURCHGOTT, ROBERT F. 

FOR THEIR DISCOVERIES CONCERNING NITRIC OXIDE AS A SIGNALING MOLECULE IN THE CARDIOVASCULAR SYSTEM

2000 GREENGARD, PAUL 

FOR THEIR DISCOVERIES CONCERNING SIGNAL TRANSDUCTION IN THE NERVOUS SYSTEM

2000 KANDEL, ERIC R. 

FOR THEIR DISCOVERIES CONCERNING SIGNAL TRANSDUCTION IN THE NERVOUS SYSTEM

2002 BRENNER, SYDNEY 

FOR THEIR DISCOVERIES CONCERNING GENETIC REGULATION OF ORGAN DEVELOPMENT AND PROGRAMMED CELL DEATH

2002 HORVITZ, H. ROBERT 

FOR THEIR DISCOVERIES CONCERNING GENETIC REGULATION OF ORGAN DEVELOPMENT AND PROGRAMMED CELL DEATH

2004 AXEL, RICHARD

FOR THEIR DISCOVERIES OF ODORANT RECEPTORS AND THE ORGANIZATION OF THE OLFACTORY SYSTEM

2006 FIRE, ANDREW Z. 

FOR THEIR DISCOVERY OF RNA INTERFERENCE - GENE SILENCING BY DOUBLE-STRANDED RNA

2011 STEINMAN, RALPH M. 

FOR THEIR DISCOVERIES CONCERNING THE ACTIVATION OF INNATE IMMUNITY

2011 BEUTLER, BRUCE A. 

FOR THEIR DISCOVERIES CONCERNING THE ACTIVATION OF INNATE IMMUNITY

2013 SCHEKMAN, RANDY W.

FOR THEIR DISCOVERIES OF MACHINERY REGULATING VESICLE TRAFFIC, A MAJOR TRANSPORT SYSTEM IN OUR CELLS

2013 ROTHMAN, JAMES E. 

FOR THEIR DISCOVERIES OF MACHINERY REGULATING VESICLE TRAFFIC, A MAJOR TRANSPORT SYSTEM IN OUR CELLS

2017 ROSBASH, MICHAEL

FOR THEIR DISCOVERIES OF MOLECULAR MECHANISMS CONTROLLING THE CIRCADIAN RHYTHM

Likud Herut UK

[evil-jennifer-hamilton-wb]

What is ur favourite prokaryote out of all of them cause my favourite has to be cyanobacteria they are so cool and independent and while being prokaryotic have almost identical pigments to that of higher plants?? Can perform oxygenic photosynthesis??? Like u would think this is some microsized plant or somethin but nooooo it has a rigid cell wall and flagella too if needed be. An iconic life form truly no one is doin it like her

For sure cyanobacteria is iconic! Likely her ancestors were responsible for endosymbiosis with early eucaryotes to become the modern chloroplast. Vital phytoplankton for many a marine ecosystem.

However... My favorite prokaryote should be clear enough from my signature and past posting. Escherichia Coli is my favorite prokaryote.

She's present in many animal gut microbiomes, humans included. She's the model organism! From E-coli we sequence the bacterial genome, we produce proteins via recombination! Universality of genetic code! Insulin and other peptide hormones all come from her! We've modeled various protein secondary structures like the structure of ATP-Synthase! She's simple, elegant, beautiful!

An icon, the model for all life.

[peptide-ltd]

Fitness Product---ACE 031 Peptide

ACE 031 Peptide: What is it?

ACE-031 peptide is a recombinant fusion protein made by combining part of the human natural myostatin (ActRIIB) receptor with part of a human antibody. ACE-031 is a myostatin inhibitor that can inhibit the binding of myostatin to the receptor, thereby increasing muscle mass and strength. Many clinical studies have shown that ACR-031 peptide can play a role in alleviating some diseases with symptoms of muscle atrophy.

What is the mechanism of ACE-031 peptide?

The mechanism of action of ACE-031 is related to negative regulators of muscle growth. It enhances the activity of the muscle growth system by interacting with myostatin and other related proteins.

Myostatin is a negative regulator protein that inhibits muscle growth. When it binds to ActRIIB on muscle cells, it inhibits muscle cell differentiation and growth. ACE-031 can target myostatin to prevent it from interacting with the ActRIIB receptor to increase muscle mass and muscle strength.

The mechanism of action of ACE-031 is mainly to regulate muscle mass and muscle growth to treat diseases related to muscle atrophy.

[sudheervanguri]

ALS Testing Services India Private Limited  Recruitment Notification About ALS Global & Job Descriptions We Are Hiring Passionate Professionals in Life Sciences ALS Global is expanding into Biologics and Complex Generics Analytical Testing Services with our new brownfield project in Hyderabad. We have multiple openings for experienced professionals ready to make an impact in the life sciences industry. About ALS Global: ALS Global is a leading provider of testing, inspection, certification, and verification services, offering a wide range of solutions across industries, including life sciences, environmental, food, pharmaceutical, and more. With over 350 laboratories in more than 65 countries, ALS delivers tailored, scientifically sound, and reliable testing services, meeting the highest quality standards. We are expanding our life sciences division to include comprehensive analytical support for biologics and complex generics at our new Hyderabad facility. To learn more about ALS, visit www.alsglobal.com. Now Hiring for Hyderabad Brownfield Project: ALS Global is extending its services to provide tailored, scientifically sound, and reliable solutions in the life sciences domain, specifically for Biologics and Complex Generics Analytical Testing Services. We are seeking passionate candidates for our new brownfield project at Hyderabad. We have multiple openings across various levels, including: Tech Leads Team Leads Research Scientists Research Associates Executives Sr. Executives Domains & Key Areas of Expertise: 1. Analytical Characterization and Testing of Therapeutic Peptides, Proteins, and Oligos Qualifications: PhD / M.Tech / Pharm / MSc Experience: 3-8 years Key Responsibilities: Perform analytical characterization of therapeutic peptides (synthetic and recombinant), proteins, and oligonucleotides. Characterize primary structure, higher-order structures, product variants, and related impurities using various analytical techniques. Develop and validate methods using a Quality by Design (QBD) approach. Hands-on Experience with: Mass Spectrometry Methods: LCMS, HRMS, MALDI. Chromatographic Methods: HPLC/UPLC (Reverse Phase, Size Exclusion, Ion Exchange, Ion Chromatography), Peptide Mapping, Glycan Analysis. Spectroscopic Methods: Circular Dichroism (CD), UV-Vis, FT IR, Fluorescence. Electrophoresis Techniques: Gel electrophoresis, Capillary Electrophoresis (CE), CE SDS, Capillary Isoelectric Focusing (CIEF). Other Techniques: Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC), Differential Scanning Calorimetry (DSC), Amino Acid Analysis (AAA). Ensure compliance with regulatory requirements and contribute to protocol and report preparation. 2. Cell-Based, Cell-Free Based, and Immunogenicity Testing Qualifications: PhD / M.Tech / MSc / B.Tech Experience: 3-8 years Key Responsibilities: Hands-on experience with mammalian cell culture and maintenance techniques, including cell-based bioassays, fluorescence assays, and immunoassays. Develop and validate cell-based bioassays for therapeutic peptides, proteins, and oligos. Experience in the development and validation of ELISA-based methods. Handle Peripheral Blood Mononuclear Cells (PBMCs) and perform immunogenicity-based testing. Operate equipment such as multimode readers and flow cytometers. Conduct qualification and commissioning of analytical equipment. Ensure knowledge of 21 CFR compliance, with a preference for experience in Contract Research Organizations (CROs). Prepare protocols, validation reports, and comply with regulatory guidelines. 3. Microbiology Testing Qualifications: PhD / M.Tech / MSc / B.Tech Experience: 3-8 years Key Responsibilities: Conduct Bacterial Endotoxin Testing (BET) on water, raw materials, and in-process samples. Develop and validate antimicrobial effectiveness testing. Perform microbiological assay batch release testing, including microbial limit testing, bioburden analysis, and sterility testing using isolator technology.

Conduct growth promotion tests and in vitro kill rate studies. Perform qualification and commissioning of microbiological analytical equipment. Ensure compliance with 21 CFR and other regulatory requirements, with a preference for those with experience in CROs. Prepare protocols and reports for validation and analysis. Open Positions: Tech Leads / Team Leads: Lead teams in method development, characterization, and validation of biologics and complex generics. Research Scientists / Research Associates: Conduct hands-on analytical testing, develop and validate methods, and ensure regulatory compliance. Executive / Sr. Executive Roles: Provide technical support for analytical and microbiological testing, method validation, and compliance activities. [caption id="attachment_106615" align="aligncenter" width="930"] ALS India career Recruitment - Job vacancies[/caption] ALS Global is committed to providing a supportive work environment, encouraging innovation, and fostering continuous improvement to provide high-quality testing and inspection services. If you are passionate about driving advancements in life sciences, we would love to hear from you! How to Apply You can submit your application by  clicking the link below, or emailing your CV directly to alsin.career@alsglobal.com. or Application Link

[healthcare-skyquest]

Biosimilars Market: Driving Affordable Healthcare Solutions

The Biosimilars market has become a significant player in modern healthcare, offering cost-effective alternatives to biologics. As the demand for affordable therapeutic options rises, the market for biosimilars is gaining substantial momentum. This article delves into the market trends, segmentation, growth drivers, and leading companies in the biosimilars industry, providing crucial insights for decision-makers.

Market Overview

According to SkyQuest's Biosimilars Market report, the global market is currently valued at USD 27.30 billion in 2023, with a projected CAGR of 16.4% over the forecast period. The market's expansion is fueled by patent expirations of key biologics, increasing prevalence of chronic diseases, and a growing emphasis on cost-efficient healthcare solutions.

Request Your Free Sample: - https://www.skyquestt.com/sample-request/biosimilars-market

Market Segmentation

By Product Type:

Recombinant Non-Glycosylated Proteins: Used in the treatment of diseases such as diabetes and cancer.

Recombinant Glycosylated Proteins: Common in oncology and autoimmune disease therapies.

Peptides: An emerging class used for metabolic diseases and cancer treatment.

By Application:

Oncology: High demand for biosimilars due to the rising incidence of cancers and the need for affordable treatments.

Chronic Diseases: Biosimilars for diabetes, arthritis, and cardiovascular diseases are critical for cost-effective long-term care.

Autoimmune Diseases: Increasing prevalence of conditions like rheumatoid arthritis and multiple sclerosis is driving the demand for biosimilars.

Infectious Diseases: Expansion of biosimilars in this sector due to the global burden of infections.

By Manufacturing Type:

In-House Manufacturing: Pharmaceutical companies developing their own biosimilars to maintain control over production.

Contract Manufacturing: Outsourcing production to specialized third-party manufacturers for efficiency and scalability.

By End-User:

Hospitals and Clinics: Major centers for biosimilars administration.

Pharmaceutical Companies: Driving the production and distribution of biosimilars.

Research Institutes: Key players in the innovation and clinical trials of biosimilars.

Key Growth Drivers

Patent Expirations of Biologics: As patents for major biologic drugs expire, the market opens up for biosimilar development.

Rising Healthcare Costs: Increasing demand for cost-effective alternatives to expensive biologic therapies.

Chronic Disease Prevalence: Growing rates of cancer, diabetes, and autoimmune diseases are spurring demand for biosimilars.

Government Initiatives: Regulatory frameworks supporting the approval and adoption of biosimilars.

Read More at: - https://www.skyquestt.com/report/biosimilars-market

Leading Companies in the Market

SkyQuest’s Biosimilars Market report highlights key players driving innovation and expansion, including:

Pfizer Inc.

Novartis AG (Sandoz)

Amgen Inc.

Samsung Bioepis

Biocon

Celltrion Healthcare

Teva Pharmaceuticals

Mylan N.V.

Fresenius Kabi

Hoffmann-La Roche Ltd

Challenges and Opportunities

The biosimilars market faces hurdles such as complex manufacturing processes and regulatory challenges. However, the growing acceptance of biosimilars by healthcare providers, coupled with increasing investments in biosimilar R&D, presents significant opportunities for market players to innovate and expand.

Take Action Now: Secure Your Report Today - https://www.skyquestt.com/buy-now/biosimilars-market

Future Outlook

As healthcare systems worldwide strive to reduce costs without compromising care quality, the biosimilars market is poised for strong growth. Companies that prioritize technological advancements, navigate regulatory frameworks efficiently, and focus on patient access will thrive in this evolving market.

The biosimilars market is shaping the future of affordable healthcare. With increasing demand for cost-effective treatments, decision-makers must keep pace with the trends and opportunities in this dynamic sector. For more comprehensive insights and strategic recommendations, consult SkyQuest’s in-depth Biosimilars Market report.

[healthcareanna]

Biosimilars Market Size, Trends, Growth Analysis 2032

Biosimilars Market Overview

An integral component of the Biosimilars Market is the emergence of follow-on biologics. These biologics, which closely resemble existing biologic drugs, offer additional options for patients and healthcare providers. Follow-on biologics undergo rigorous testing to demonstrate similarity to the reference product, ensuring interchangeability and therapeutic equivalence. With their introduction, follow-on biologics stimulate competition in the biopharmaceutical industry, driving down prices and promoting innovation. As the demand for cost-effective biologic therapies continues to grow, the Biosimilars Market stands to benefit from the availability and acceptance of follow-on biologics, expanding treatment options and improving patient outcomes.

According to Market Research Future (MRFR), the biosimilars market insights was valued at USD 29.7 billion in 2023 and is projected to grow from USD 36.79 Billion in 2024 to USD 161.95 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.35% during the forecast period (2024 - 2032).

Biosimilars Market: Latest News and Developments

The FDA has approved the first Humira biosimilar. Adalimumab-bwwd (Cyltezo), a Humira biosimilar, received FDA approval in January 2023 for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Rising use of biosimilars in the treatment of cancer. A growing number of biosimilars are being used to treat cancer. The FDA authorised filgrastim-sndz (Zarxio), pegfilgrastim-jmdb (Onpro), and trastuzumab-dkst (Herzuma) as three biosimilars for the treatment of cancer in 2022.

Market Segmentation

Biosimilars industry can be considered with respect to product, applications, and end users.

The products based on which the market has been split into are recombinant glycosylated proteins, recombinant peptides, and recombinant non-glycosylated proteins. Recombinant non-glycosylated proteins are the biggest segment in the global market, thanks to the soaring cases of chronic disorders ranging from growth hormone deficiency to diabetes. As a result, recombinant non-glycosylated proteins are therapeutically used as they are readily available and are cost-effective.

Application-wise, the biosimilars market caters to chronic diseases, oncology, blood disorders, autoimmune diseases, infectious diseases, growth hormone deficiency, and more. Blood disorders have emerged as the top segment, as a result of the rising burden of the condition worldwide and the increased use of biosimilars by virtue of their low cost and the overall reduction in the treatment cost.

Major end users in the global market are hospitals and clinics as well as research institutes. Hospital and clinics are healthcare settings where treatment options and skilled professionals are easily available, and therefore, have emerged as the leading segment in the global industry.

Regional Status

Europe, MEA or Middle East & Africa along with the Americas, APAC or Asia Pacific are the primary markets for biosimilars.

Europe has taken the lead in the global market, as the region houses a vast elderly pool, with close to one fifth of the overall EU population aged more than 65 years. This has given way to several lifestyle-related disorders such as oncology, autoimmune diseases, diabetes, to name a few. Presumably, the scenario has raised the demand for biosimilars and can mean higher market growth over the next few years. In addition to this, numerous blockbuster biologics are on track to lose patent in the coming years, which should present lucrative opportunities to the biosimilar manufacturers.

The North American market displays a bright outlook and can emerge quite lucrative in the coming years, in view of the surging burden of chronic ailments in Canada and the United States. The rising spending on research activities by the healthcare agencies also fuels the market expansion in the region. Favorable reimbursement landscape in the region, especially in the US, encourages healthy competition as it results in lower incentives for the players to compete based on price.

The APAC market is slated to witness considerable growth, with China, South Korea and India offering a host of lucrative opportunities for drug development as well as commercialization. These are generics-driven countries and are known for frequently launching new and advanced manufacturing platforms, which has brought down the costs associated with biosimilar production. In the coming few years, majority of the patent expiries is touted to be in biosimilars, which is deemed as a profitable aspect by leading manufacturers and can translate into substantial market growth.

Eminent Vendors

Top global key players listed by biosimilars market outlook report include Stada Arzneimittel AG (Germany), Teva Pharmaceuticals (Israel), Biocon (India), Pfizer (US), Sandoz International (Germany), Eli Lily & Company (US), Actavis, Inc. (US), Dr. Reddy’s Laboratories (India), Cipla Ltd (India), Amgen, Inc. (US), Samsung Biologics (South Korea), Hospira Inc.(US), Mylan, Inc.(US), Celltrion (South Korea), to mention a few.

More Related Trending Topics

Medical Foods market

Insomnia market

Blockchain Technology in Healthcare market

Drug Device Combination market

Prefilled Syringes market

[precisionantibody]

Comprehensive Mouse Monoclonal Antibody Service: Advancing Research Precision

Custom Antibody Development

Our mouse monoclonal antibody service begins with a thorough understanding of your research requirements. We offer custom antibody development tailored to your specific antigen. The process starts with antigen preparation, which can include peptides, recombinant proteins, or other antigen forms. Our team of experts collaborates closely with you to design and synthesize the optimal antigen, ensuring high immunogenicity and specificity.

Immunization and Hybridoma Production

Following antigen preparation, Mouse Monoclonal Antibody Service our service employs a meticulous immunization protocol in mice. We utilize proprietary adjuvants and immunization schedules to elicit a robust immune response. Once the mice exhibit a strong antibody response, spleen cells are harvested and fused with myeloma cells to create hybridomas. These hybridoma cells are capable of continuous growth and produce monoclonal antibodies against the target antigen.

Screening and Selection

One of the most critical steps in the mouse monoclonal antibody production process is the screening and selection of hybridomas. We employ high-throughput screening techniques, including ELISA, Western blotting, and flow cytometry, to identify hybridomas producing high-affinity antibodies. Positive clones are subjected to further validation to ensure specificity and minimal cross-reactivity. Our rigorous screening process guarantees that only the best-performing hybridomas are selected for expansion and antibody production.

Antibody Characterization and Purification

After the selection of promising hybridomas, the monoclonal antibodies are produced in larger quantities. These antibodies undergo extensive characterization to determine their binding affinity, specificity, and functional activity. Techniques such as surface plasmon resonance (SPR) and epitope mapping are used to characterize the antibodies thoroughly. Once characterized, the antibodies are purified using protein A/G affinity chromatography, ensuring high purity and yield.

Quality Control and Validation

Quality control is a cornerstone of our mouse monoclonal antibody service. Each batch of antibodies undergoes stringent quality control testing to confirm their consistency, purity, and functionality. We provide detailed validation data, including SDS-PAGE analysis, endotoxin levels, and activity assays, to give researchers confidence in the performance of our antibodies.

Custom Conjugation and Modification

To further enhance the utility of our monoclonal antibodies, we offer custom conjugation and modification services. Whether you need biotinylation, fluorescent labeling, or enzyme conjugation, our team can tailor the antibodies to suit your experimental needs. These modifications expand the application range of our antibodies, making them suitable for various assays, including immunohistochemistry, flow cytometry, and diagnostic tests.

Technical Support and Consultation

Our commitment to advancing research goes beyond antibody production. We provide comprehensive technical support and consultation throughout your project. Antibody Purification Our experienced scientists are available to assist with experimental design, troubleshooting, and data interpretation. We strive to be a valuable partner in your research journey, ensuring you get the most out of our mouse monoclonal antibody service.

[tritonmarketresearchamey]

Bioengineered Protein Drugs Market: Trends Fuel Advanced Remedies

As per IDF Diabetes Atlas 10th edition, around 537 million adults are diagnosed with diabetes globally; this number is anticipated to surge to 643 million by 2030. Type 1 diabetes is among the most common autoimmune diseases, followed by lupus, rheumatoid arthritis, and psoriasis. According to the National Stem Cell Foundation, nearly 4% of the world’s population is distressed by at least 1 out of 80+ diseases. Such high prevalence has increased the adoption of bioengineered protein medications due to high affinity and low toxicity. Based on our estimates, the global bioengineered protein drugs market is predicted to witness progress with a CAGR of 7.7% during the forecast period 2023-2030.

The burden of diseases due to the rising aging population has elevated the demand for advanced medications. As per the World Population Prospects 2019, 1 in 6 people will be over 65 globally by 2050. This has prompted advancements in biotechnology and protein engineering, resulting in the availability of various drugs, including monoclonal antibodies, peptide hormones, vaccines, and fusion proteins.

Let’s look deeper into the key trends prompting developments in drug delivery systems, leading to the bioengineered protein drugs market’s expansion.

·         Rising Chronic Cases Amplifies Recombinant Proteins’ Application

Over the past decade, the incidence rate of chronic diseases has soared due to unhealthy lifestyles. According to WHO, more than 15 million people between 30-69 years decease from chronic conditions annually. Cardiovascular disease accounts for most non-communicable disease mortality, followed by cancers, diabetes, etc. This has led to a significant shift in the pharmaceutical industry from chemical drugs to protein drug development. For instance, between 2021 and 2022, the US FDA approved 19 mAbs, 6 peptide hormones, 1 fusion protein, 4 therapeutic enzymes, etc.

Protein drugs using recombinant DNA technology have gained significant traction recently, leading to various launches. For instance, in February 2023, Researchers at the Indian Institute of Technology (IIT) Guwahati developed a ‘Recombinant Protein Toolbox’ consisting of six proteins that convert skin cells into heart cells, especially cardiomyocytes. This toolbox regenerates damaged heart tissues using DNA technology.

·         Manufacturing Advancements Widen Drug Scope

Earlier, protein drugs were obtained from humans or other resources. For example, vaccines were formulated using egg cultures. However, recombinant DNA technology has enabled manufacturers to produce bioengineered protein drugs like vaccines, monoclonal antibodies, and blood factors using genetically modified organisms. To elucidate, blood products can be manufactured using DNA technology in bacterial expression or mammalian cell culture systems. The prominence of protein engineering platform technologies is mainly owing to their ability to enhance medications’ functionality, purity, and circulating half-life. Protein conjugation and derivatization are among the major approaches that elevate circulating half-life.

Advancements in protein engineering have led to further R&D investments in protein-based drug manufacturing. For instance, in March 2023, Eli Lilly and Company invested $1.5 billion to expand its manufacturing footprint with new facilities in North Carolina, Indiana, and Ireland. Its facility in Ireland is set to be the most technically advanced manufacturing site for existing monoclonal antibodies, producing existing and pipeline clinical products by 2026. Hence, drug manufacturing and delivery advancements create opportunities for the bioengineered protein drugs market.

Growth Projections: R&D Expands Treatment Possibilities

Considering the rising demand for effective therapies and high unmet needs, healthcare companies are surpassing research boundaries to improve treatments. This has led the pharmaceutical industry to move towards novel molecular formats to deliver breakthrough therapies. Moreover, rare diseases with few or no treatment drugs have influenced players to expand research capabilities and launch new drugs. Since numerous factors drive many complex conditions, constraining one target may not prosper in achieving efficiency. In such a scenario, developing multi-specific antibody formats treats multi-layered diseases by engaging two or more targets with one molecule. Therefore, rising research and development activities are expected to boost the bioengineered protein drugs market.

 

FAQs:

Q1) Which region holds the highest share in the bioengineered protein drugs market?

North America holds the highest share of the global market.

Q2) Which are the major bioengineered protein drug types?

Monoclonal antibodies, peptide hormones, vaccines, blood factors & peptide antibiotics, fusion proteins, cytokines, and therapeutic enzymes are major drug types.

[123567-9qaaq9]

Protein Production Technologies Outlines, Future Trends, Insight And Quality Analysis 

Protein production technologies represent the backbone of modern biotechnology, driving innovation across multiple industries including pharmaceuticals, agriculture, and biomanufacturing. . 

The Protein Production Technologies  was valued at $2,393.0 million in 2023 and is expected to reach $6,963.6 million by 2033, growing at a CAGR of 11.27% between 2023 and 2033

Gene Expression Analysis Overview 

Protein production technologies encompass a diverse array of methodologies, tools, and techniques utilized to generate proteins for various applications in research, medicine, industry, and beyond. These technologies are designed to efficiently produce recombinant proteins, peptides, and other biomolecules, either in living organisms (in vivo) or in laboratory settings (in vitro).

In vivo protein production technologies typically involve genetically engineering host organisms, such as bacteria, yeast, insect cells, or mammalian cells, to express specific proteins of interest. This can be achieved through the use of expression vectors containing the gene encoding the target protein, along with regulatory elements to drive its expression.

Market Segmentation

Segmentation 1: By Application

Segmentation 2: By End User 

Segmentation 3: By Product

Segmentation 4: By Expression System

Segmentation 5: By Region

Protein expression in North America is a dynamic and crucial field with a significant impact across industries. 

The region, especially North America, is a global leader in biopharmaceuticals, relying extensively on protein expression for producing biologics, including monoclonal antibodies and vaccines. 

North America holds the largest share of the Protein Production Technologies 

Download our sample page now click here !

Application for  Recombinant Protein Production Technologies  

Drug Discovery 

Structural Biology 

Disease Modelling 

Enzyme Production 

Vaccines Development 

Therapeutic Proteins 

Immunoassays 

Key Market Players 

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Charles River Laboratories International, Inc.

Danaher Corporation (Abcam plc.)

GenCefe Co., Ltd.

Genscript Biotech Corporation

And many others 

Market Dynamics

Market Drivers 

Increasing Demand for Protein Biologics Creating the Need for Protein Expression 

Market Restraints 

Long and Complicated Regulatory Timelines and Approvals of Recombinant Proteins and Biologics

Market Opportunities 

Rising Awareness of Proteomics in Emerging Countries 

 Visit our Life Sciences & Biopharma page for better understanding 

Key factors contributing to the growth of the recombinant Protein Production Technologies  

Expanding applications of recombinant proteins in drug discovery, biomanufacturing, and diagnostic assays

Rising prevalence of chronic diseases and the need for innovative therapies.

Recent Developments in the Recombinant Protein Production Technologies 

In January 2024, Evosep, a leader in sample preparation for mass spectrometry-based proteomics, partnered with Thermo Fisher Scientific Inc., a global scientific leader, to advance clinical proteomics research. This collaboration would combine Evosep's sample separation technology with Thermo Fisher Scientific Inc.'s mass spectrometry instruments, enhancing proteomics research capabilities.release would support pharmaceutical and biotechnology companies engaged in the manufacturing of therapeutic proteins, with the goal of improving product quality and expediting time-to-market.

Key Questions Answered 

Q What is the estimated global market size for the Protein Production Technologies ?

Q What are the future trends expected in the Protein Production Technologies ?

Q What does the supply chain and value chain of the Protein Production Technologies  look like?

Q  What is the regulatory framework of the Protein Production Technologies ?

Q How has the COVID-19 outbreak affected the future trajectory of the Protein Production Technologies ?

Q What are the market entry barriers and opportunities in the Protein Production Technologies ?

Q What are the major market drivers, challenges, and opportunities of the Protein Production Technologies ?

Q How is each segment of the Protein Production Technologies  expected to grow during the forecast period, and what is the anticipated revenue generated by each of the segments by the end of 2033?

Q What is the growth potential of the global Protein Production Technologies  in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World, and what are the driving and challenging factors of the market in each of these regions?

Q Who are the leading players with significant offerings in the Protein Production Technologies , and what is the current market dominance for each of these leading players? Who are the next frontiers in the Protein Production Technologies ?

Conclusion 

In conclusion, the Protein Production Technologies  continues to thrive and evolve as a vital component of numerous industries, including biotechnology, pharmaceuticals, agriculture, and research

[peptide-synthesis]

Services for peptide development and analysis

Peptides, the building blocks of proteins, play a crucial role in various biological processes. As the demand for peptides continues to rise in industries such as pharmaceuticals, cosmetics, and agriculture, the need for reliable peptide development and analytical services becomes increasingly evident. In this article, we delve into the world of peptide analysis and synthesis, exploring the significance of these services and their impact on diverse sectors.

Introduction to Peptide Development and Analytical Services

Peptide development and analytical services encompass a range of techniques and methodologies aimed at synthesising and analysing peptides with precision and accuracy. These services are vital for ensuring the quality, purity, and efficacy of peptides intended for various applications.

Importance of Peptide Analytical Services

Peptide analytical services play a pivotal role in the pharmaceutical industry, where the quality and purity of peptides directly impact drug development and efficacy. By employing advanced analytical techniques, such as HPLC (High-Performance Liquid Chromatography) and mass spectrometry, service providers can verify the identity, purity, and quantity of synthesised peptides, ensuring compliance with regulatory standards.

Understanding Peptide Synthesis

Peptide synthesis is the process of creating peptides by linking together amino acids in a specific sequence. This process can be achieved through solid-phase synthesis, liquid-phase synthesis, or recombinant DNA technology. Each method has its advantages and limitations, and the choice of synthesis method depends on factors such as peptide length, complexity, and desired purity.

Factors Influencing Peptide Synthesis

Several factors influence the success of peptide synthesis, including the choice of amino acids, coupling reagents, protecting groups, and reaction conditions. Optimising these parameters is essential for achieving high yields and purity in peptide synthesis.

Types of Peptide Analytical Techniques

Peptide analytical services employ various techniques to characterise and analyse peptides, including:

HPLC Analysis

HPLC is a powerful analytical technique used for separating, identifying, and quantifying components in a mixture. In peptide analysis, HPLC is commonly used for assessing purity, identifying impurities, and determining the concentration of synthesised peptides.

Mass Spectrometry

Mass spectrometry allows for the precise determination of the molecular weight and composition of peptides. By ionising peptides and analysing their mass-to-charge ratio, mass spectrometry provides valuable information about peptide identity, purity, and structural integrity.

NMR Spectroscopy

Nuclear Magnetic Resonance (NMR) spectroscopy is another important tool for peptide analysis, offering insights into peptide structure, conformation, and interactions. NMR can elucidate the three-dimensional structure of peptides, aiding in drug discovery and design.

Benefits of Utilising Peptide Analytical Services

The utilisation of peptide analytical services offers several benefits, including:

Ensuring the quality and purity of synthesised peptides.

Facilitating the characterization and structural elucidation of peptides.

Accelerating drug discovery and development processes.

Meeting regulatory requirements and quality standards.

Choosing the Right Peptide Analytical Service Provider

When selecting a peptide analytical service provider, it is essential to consider factors such as expertise, reputation, technological capabilities, and turnaround time. Partnering with a reliable and experienced service provider is crucial for obtaining accurate and reliable analytical results.

Case Studies: Successful Peptide Development Stories

Several success stories exemplify the importance of peptide development and analytical services in various industries. From the discovery of novel therapeutic peptides to the development of peptide-based diagnostics and biomaterials, these case studies highlight the transformative potential of peptide research and innovation.

Future Trends in Peptide Analysis and Synthesis

The field of peptide analysis and synthesis is continually evolving, driven by advancements in technology, automation, and computational methods. Future trends may include the development of novel synthesis strategies, the integration of artificial intelligence in peptide design, and the emergence of miniaturised analytical platforms for rapid peptide characterization.

Conclusion

In conclusion, peptide development and analytical services play a crucial role in ensuring the quality, purity, and efficacy of peptides for diverse applications. By harnessing advanced analytical techniques and synthesis methodologies, service providers enable advancements in drug discovery, diagnostics, and biotechnology. As the demand for peptides continues to grow, the importance of reliable analytical services cannot be overstated.

[awesomechrisharry]

Biosimilars Revolution: Navigating Recombinant Glycosylated Proteins, Non-glycosylated Proteins, and Peptides

Biosimilars have emerged as a transformative force in the pharmaceutical industry, offering cost-effective alternatives to biologics. This article delves into the biosimilars market, focusing on three key product categories: Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides. Each of these categories plays a vital role in addressing diverse medical needs, from chronic diseases to oncology treatments.

Recombinant Glycosylated Proteins:

Glycosylated proteins constitute a significant portion of the biosimilars market. This category includes essential biologics like insulin and monoclonal antibodies. The glycosylation process, involving the addition of sugar molecules, impacts the protein's stability, activity, and pharmacokinetics. Recombinant Glycosylated Proteins biosimilars are vital in treating a range of conditions, offering a more affordable option without compromising efficacy.

Recombinant Non-glycosylated Proteins:

The Recombinant Non-Glycosylated Proteins segment is a key player in biosimilar development. Comprising proteins such as granulocyte colony-stimulating factors, interferons, and human growth factors, this category offers alternatives to biologics that do not undergo glycosylation. The demand for these biosimilars is on the rise, driven by the prevalence of chronic diseases and changing regulations that prioritize cost-effective yet efficacious treatments.

Recombinant Peptides:

The biosimilars market is witnessing a surge in the development of Recombinant Peptides. Peptides are short chains of amino acids with diverse therapeutic applications, including diabetes, cancer, and autoimmune disorders. Biosimilar peptides offer a promising avenue for addressing unmet medical needs. The cost-effectiveness and potential for personalized medicine make Recombinant Peptides a compelling area of focus for pharmaceutical companies.

Market Dynamics and Growth Drivers:

The biosimilars market is propelled by the increasing prevalence of chronic diseases, the expiration of biologic patents, and the need for cost-effective healthcare solutions. The demand for biosimilars in oncology treatments, driven by advancements in biomedical technology, further fuels market growth. Changing government regulations worldwide are fostering an environment conducive to biosimilar development, offering patients access to affordable alternatives.

Regional Insights:

As the biosimilars landscape evolves, Europe remains a frontrunner, accounting for a substantial share of the global market. The region's mature biosimilars market, marked by a robust regulatory framework, positions it as a key player in the industry. Other regions are also witnessing growth, with an increasing number of approvals and a focus on expanding biosimilar portfolios. The biosimilars market, with a spotlight on Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides, continues to reshape the pharmaceutical landscape. As technology advances and regulatory support grows, biosimilars are poised to become indispensable in providing accessible and cost-effective treatments for a wide range of medical conditions. This dynamic environment, marked by strategic advancements and collaborations, underscores the pivotal role biosimilars play in the future of healthcare.

[sudheervanguri]

Mankind Pharma Hiring Research Scientists / Senior Research Scientists in Manesar, Gurugram - MTech/PhD in Biotechnology Required Mankind Pharma, a leading pharmaceutical company, is seeking qualified candidates for the positions of Research Scientist and Senior Research Scientist in their biotech division. The roles are based in Manesar, Gurugram, Haryana. Candidates with a background in Biotechnology, specifically MTech or PhD holders, and 3-5 years of relevant experience are encouraged to apply. About Mankind Pharma Mankind Pharma is a globally recognized pharmaceutical company known for its innovative approach and commitment to quality. The company is dedicated to improving healthcare and making medicines accessible to all. Mankind Pharma’s biotech division focuses on cutting-edge research and development to bring new therapies to market. Job Details and Qualifications Research Scientist / Senior Research Scientist Department: Biotechnology Experience: 3-5 Years Qualification: MTech (Biotechnology) / PhD (Biotechnology) Work Location: Manesar, Gurugram, Haryana Job Description: The ideal candidate should have a solid understanding of recombinant proteins, biophysical methods, and similarity analysis of biosimilars. Key responsibilities include: Handling HRMS/LCMS systems for method development. Characterizing monoclonal antibodies (mAbs) using HRMS/LCMS techniques such as peptide mapping and glycan analysis. Identifying post-translational modifications of mAbs. Qualifying and validating developed methods. Preparing Standard Test Procedures (STPs), Standard Operating Procedures (SOPs), and related documentation. Additional Open Positions Group Leader Department: Pharmacokinetics-Clinical Experience: 8-10 Years Qualification: Masters in Pharmaceutical Sciences Work Location: Manesar, Gurugram, Haryana Job Description: Responsibilities include protocol preparation, review, study design, pharmacokinetic data analysis, scientific interpretation of BA/BE study results, and report writing. Proficiency with pharmacokinetic software programs like Phoenix, PK data modeling and simulations, and knowledge of global regulatory guidelines is required. Research Scientist / Senior Research Scientist Department: Peptides-Analytical API Experience: 5-7 Years Qualification: MSc / PhD in Analytical/Organic Chemistry Work Location: Manesar, Gurugram, Haryana Job Description: Candidates should have experience in analytical development, including related impurities, peptide assays, and amino acid ratio analysis. Hands-on experience with preparative LC & DAC purification techniques and method development for peptides is essential. Research Scientist / Senior Research Scientist Department: Peptides-Analytical API (Plant Scale-Up) Experience: 5-7 Years Qualification: BTech (Chemical Engineering) / MSc / PhD in Analytical/Organic Chemistry Work Location: Manesar, Gurugram, Haryana Job Description: Experience in purification/isolation and scale-up at the plant level is crucial. Candidates should be proficient with preparative LC & DAC techniques at lab and plant scales and knowledgeable about chromatography, GMP systems, and team management. [caption id="attachment_59502" align="aligncenter" width="930"] Mankind pharma Recruitment Notification[/caption] How to Apply Interested candidates should email their CV to careers.rnd@mankindpharma.com. Only relevant CVs will be considered. Immediate joining is preferred.

[medchemexpressinhibitor-blog]

 Unraveling the Role of Brain Natriuretic Peptide in Cardiovascular Health

Introduction

Within the complex realm of cardiovascular health, a protein called Brain Natriuretic Peptide (BNP) has emerged as a significant biomarker and therapeutic target. This hormone, primarily produced by the heart, plays a crucial role in regulating blood pressure and fluid balance. In this article, we will delve into the fascinating world of BNP protein, exploring its functions, clinical significance, and factual evidence supporting its role in cardiovascular health.

Understanding BNP Protein

Brain Natriuretic Peptide (BNP) is a hormone synthesized and secreted by the ventricles of the heart, primarily in response to increased cardiac wall stress and stretching caused by conditions such as heart failure or hypertension. BNP belongs to a family of hormones known as natriuretic peptides, which exert various effects on the cardiovascular system.

The Functions of BNP Protein

Regulation of Blood Pressure: BNP acts as a vasodilator, causing blood vessels to widen, thereby reducing peripheral resistance and lowering blood pressure. It also inhibits the release of renin, an enzyme involved in blood pressure regulation. These actions contribute to the maintenance of normal blood pressure levels[^1^].

Fluid Balance: BNP promotes diuresis (increased urine production) and natriuresis (increased sodium excretion), helping to regulate fluid balance within the body. By promoting the elimination of excess fluid, BNP aids in preventing fluid overload commonly associated with heart failure[^2^].

Cardiac Remodeling: Elevated levels of BNP often indicate underlying cardiac stress or dysfunction. BNP helps counteract harmful cardiac remodeling by inhibiting the growth of cardiac muscle cells and fibroblasts. This property can help prevent adverse structural changes in the heart associated with conditions like heart failure[^3^].

Factual Evidence Supporting BNP Protein

Clinical Studies: Numerous clinical studies have investigated the role of BNP in cardiovascular health. These studies have provided valuable insights into the diagnostic and prognostic value of BNP levels, especially in heart failure patients. Elevated BNP levels have been shown to correlate with disease severity, prognosis, and response to therapy[^4^].

Therapeutic Applications: BNP-based therapies, such as recombinant human BNP (rhBNP), have been developed for the management of acute heart failure. Controlled clinical trials have demonstrated the efficacy of rhBNP in improving symptoms, reducing hospitalizations, and enhancing overall quality of life for heart failure patients[^5^].

Guidelines and Recommendations: Leading cardiovascular societies and organizations have incorporated BNP testing into their guidelines for heart failure diagnosis and management. For instance, the American Heart Association (AHA) and the European Society of Cardiology (ESC) recommend measuring BNP levels in patients presenting with symptoms suggestive of heart failure[^6^][^7^].

Conclusion

Brain Natriuretic Peptide (BNP) protein serves as a crucial biomarker and therapeutic target in cardiovascular health. Its ability to regulate blood pressure, promote fluid balance, and hinder adverse cardiac remodeling makes it a vital component within the complex physiology of the cardiovascular system. The factual evidence obtained from clinical studies, therapeutic applications, and guideline recommendations underscores the significance of BNP in diagnosing and managing heart failure. Further research and advancements in BNP-related interventions may pave the way for improved cardiovascular care, leading to better outcomes and enhanced quality of life for patients,please visit MedChemExpress.

(Note: It is important to consult with medical professionals or experts for specific advice or information related to individual health conditions.)